NCT01253811View on ClinicalTrials.gov

Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency

PHASE3CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Congenital Bleeding DisorderCongenital FXIII Deficiency
Interventions
DRUG

catridecacog

Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week

Trial Locations (4)

43205

Novo Nordisk Clinical Trial Call Center, Columbus

49100

Petah Tikva

02115

Novo Nordisk Clinical Trial Call Center, Boston

LE1 5WW

Leicester

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY